Clinical Trials

Desmopressin acetate has been evaluated in numerous clinical trials spanning Phase 1 through Phase 4, alongside early phase studies. Research sponsored by academic and medical institutions—such as Menoufia University, Aarhus University, the National Institute of Neurological Disorders and Stroke, and Hamilton Health Sciences Corporation—has addressed conditions including nocturnal enuresis, polyuria, sellar masses, and perioperative surgical bleeding. Notable protocols include a completed evaluation in pediatric monosymptomatic nocturnal enuresis (NCT06772584), an ongoing diagnostic stimulation study for Cushing's disease (NCT04569591), and a Phase 3 trial targeting bleeding control in surgical patients with kidney injury (NCT06337838). Current recruitment statuses across these protocols encompass completed, actively recruiting, enrolling by invitation, and terminated statuses.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06635629 RECRUITING
Cushing Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
 2024-12-12 PHASE2
NCT07712328 ENROLLING_BY_INVITATION
Craniopharyngiomas; Pituitary Macroadenoma; Sellar and Suprasellar Masses
Zhaoyun Zhang
 2026-06-02 PHASE4
NCT04569591 RECRUITING
Cushing's Disease; Pituitary Adenoma
National Institute of Neurological Disorders and Stroke (NINDS)
 2026-03-09
NCT07012837 NOT_YET_RECRUITING
Adult Patients Undergoing Cardiac Surgery; High Bleeding Risks; Planned Elective Cardiac Surgery Using CPB
Imam Abdulrahman Bin Faisal University
 2025-07 PHASE3
NCT07776977 RECRUITING
Primary Monosymptomatic Nocturnal Enuresis
Al-Azhar University
 2026-08-20
NCT06883851 RECRUITING
Primary Nocturnal Enuresis; Nocturnal Enuresis in Children
Bahçeşehir University
 2025-03-11
NCT06337838 RECRUITING
Chronic Kidney Diseases; Acute Kidney Injury; Bleeding; Surgery
Hamilton Health Sciences Corporation
 2025-06-09 PHASE3
NCT05467033 RECRUITING
Kidney Biopsy
Medical University of Bialystok
 2022-09-01 PHASE3
NCT06622187 ENROLLING_BY_INVITATION
Bleeding; Transplant, Kidney; Desmopressin; Kidney Biopsy
Hospital de Clinicas de Porto Alegre
 2024-08-14 PHASE4
NCT06771128 COMPLETED
Nocturnal Enuresis in Children; Desmopressin; Monosymptomatic Nocturnal Enuresis
Menoufia University
 2024-11-01
NCT07199894 RECRUITING
Nocturnal Enuresis in Children
Mansoura University
 2024-12-01 PHASE3
NCT07292753 COMPLETED
Nocturnal Enuresis; Vitamin D Deficiency
Ain Shams University
 2024-12-15
NCT06255366 UNKNOWN
Lumbar Spondylolisthesis; Arthrosis; Spine
Chengdu University of Traditional Chinese Medicine
 2024-03-28 PHASE4
NCT06772584 COMPLETED
Enuresis, Nocturnal
Menoufia University
 2024-01-01
NCT06285006 UNKNOWN
Nocturnal Enuresis
Al-Azhar University
 2024-02-23
NCT05517590 COMPLETED
Leiomyoma, Uterine; Intraoperative Blood Loss
Acibadem University
 2022-09-01
NCT06185361 UNKNOWN
Nocturnal Enuresis; Enuresis; Enuresis, Nocturnal
Fayoum University Hospital
 2022-12-01
NCT05945420 UNKNOWN
Nocturnal Polyurea in Patients With BPH
Mansoura University
 2023-07-20 PHASE4
NCT05399173 UNKNOWN
Non-Specific Urethritis
Cairo University
 2022-06-02
NCT05617664 UNKNOWN
Nocturnal Enuresis
Benha University
 2022-11-23
NCT04420585 TERMINATED
Nocturnal Enuresis; Anemia, Sickle Cell
Montefiore Medical Center
 2020-07-07 PHASE4
NCT05507476 COMPLETED
Anesthesia
Zagazig University
 2022-09-01
NCT03389412 COMPLETED
Enuresis, Nocturnal
University of Aarhus
 2017-10-01 PHASE4
NCT05430048 COMPLETED
Bleeding
Zagazig University
 2022-07-01 PHASE2
NCT03696121 COMPLETED
Stroke, Acute
University of Nottingham
 2019-04-01 PHASE2
NCT04586790 UNKNOWN
Spinal Shock
Ahmed talaat ahmed aly
 2020-10-15 PHASE2
NCT04545931 UNKNOWN
Primary Monosymptomatic Nocturnal Enuresis
Cairo University
 2020-03-15 PHASE4
NCT04103034 COMPLETED
Cerebrovascular Stroke; Large-Artery Atherosclerosis (Embolus/Thrombosis); Intracranial Arteriosclerosis
Band Therapeutics
 2019-10-07 PHASE1
NCT04113005 UNKNOWN
Castrate Resistance Prostate Cancer
Sunnybrook Health Sciences Centre
 2019-10-01 EARLY_PHASE1
NCT03733873 COMPLETED
Monosymptomatic Nocturnal Enuresis
Children's Hospital of Fudan University
 2018-09-01
NCT03201419 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2017-07-27 PHASE2
NCT03676361 WITHDRAWN
Kidney Damage
University of Kansas Medical Center
 2018-08-29 PHASE4
NCT03051009 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2017-01-11 PHASE3
NCT02506023 COMPLETED
Hemophilia A
Emory University
 2015-07 PHASE1
NCT02584231 COMPLETED
Monosymptomatic Nocturnal Enuresis
University Ghent
 2015-09-09 PHASE4
NCT03510975 COMPLETED
Nocturnal Enuresis
Ankara Training and Research Hospital
 2015-01-01 PHASE4
NCT03343418 UNKNOWN
C.Surgical Procedure; Cardiac; Blood Coagulation Disorders
Instituto do Coracao
 2015-02 PHASE4
NCT02904759 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2016-09 PHASE3
NCT02905682 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2016-09 PHASE3
NCT01623206 COMPLETED
Colorectal Cancer; Rectal Bleeding
Laboratorio Elea Phoenix S.A.
 2013-04 PHASE2
NCT00223717 COMPLETED
Hypertension
Vanderbilt University
 2001-01 PHASE1
NCT02937896 COMPLETED
Renal Colic
Shahid Beheshti University of Medical Sciences
 2015-01
NCT02262936 TERMINATED
Nocturia
Mount Sinai Hospital, Canada
 2015-07 PHASE2; PHASE3
NCT01606072 COMPLETED
Breast Cancer
Laboratorio Elea Phoenix S.A.
 2011-11 PHASE2
NCT01530451 TERMINATED
Nocturia; Obstructive Sleep Apnoea
Chinese University of Hong Kong
 2012-03 PHASE3
NCT02068560 COMPLETED
Gender Difference in V2 Receptor Function in Response to dDAVP Infusion; Nocturia; Nocturnal Enuresis
University of Aarhus
 2012-05
NCT01729819 COMPLETED
Overactive Bladder
Ferring Pharmaceuticals
 2013-01 PHASE2
NCT02125188 COMPLETED
Patients Undergoing Endoscopic Sinus Surgery
Tao Zhang
 2014-01 PHASE4
NCT01779466 TERMINATED
Nocturia
Ferring Pharmaceuticals
 2013-04 PHASE2
NCT02084342 UNKNOWN
Idiopathic Scoliosis
Liu Weifeng
 2013-12
NCT01582542 UNKNOWN
Nocturnal Enuresis
Rabin Medical Center
 2012-04 PHASE4
NCT00961532 COMPLETED
Intracerebral Hemorrhage
Northwestern University
 2010-12 PHASE2
NCT01694498 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2012-09 PHASE2
NCT01435083 COMPLETED
Nocturnal Polyuria
University Hospital, Ghent
 2011-11 PHASE4
NCT01684800 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2012-09 PHASE2
NCT01841515 COMPLETED
Bleeding; Tachycardia; Dyspnea
University of Ulsan
 2012-08 PHASE1
NCT01742689 UNKNOWN
Renal Colic; Pain
Tehran University of Medical Sciences
 2012-03 PHASE3
NCT01439997 COMPLETED
Nocturia
University Hospital, Ghent
 2012-03-26 PHASE4
NCT01645475 COMPLETED
Monosymptomatic Nocturnal Enuresis
University Hospital, Ghent
 2011-04 PHASE4
NCT01382134 COMPLETED
Platelet Dysfunction; Hemodilution; Mild Hypothermia; NSAID; Desmopressin
The University of Hong Kong
 2011-07
NCT01552343 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2012-03 PHASE3
NCT00885924 TERMINATED
Hemorrhage; Postoperative Blood Loss
St. Olavs Hospital
 2009-03 PHASE4
NCT01262456 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2011-02 PHASE3
NCT01223937 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2010-11 PHASE3
NCT01280188 COMPLETED
Central Diabetes Insipidus
Ferring Pharmaceuticals
 2011-01 PHASE3
NCT01184859 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2010-07 PHASE2
NCT00902057 UNKNOWN
Hypothermia Induced Impairment of Primary Haemostasis
The University of Hong Kong
 2009-06 PHASE4
NCT00806468 TERMINATED
Parkinson Disease
Johannes Gutenberg University Mainz
 2009-02 PHASE4
NCT01078753 COMPLETED
Nocturnal Enuresis
Ferring Pharmaceuticals
 2010-01 PHASE3
NCT00615836 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2007-12 PHASE3
NCT01036841 COMPLETED
Enuresis; Polyuria
University Hospital, Ghent
 2009-12 PHASE4
NCT01994330 COMPLETED
Acquired Von Willebrand Disease Secondary to Severe Aortic Stenosis; Heye´s Syndrome; Severe Aortic Stenosis
Pontificia Universidad Catolica de Chile
 2009-06 PHASE4
NCT00337766 COMPLETED
Hemorrhage; Blood Loss, Surgical; Postoperative Hemorrhage
Università Vita-Salute San Raffaele
 2006-06 PHASE4
NCT00477490 COMPLETED
Nocturia
Ferring Pharmaceuticals
 2007-05 PHASE3
NCT00816127 COMPLETED
Liver Cirrhosis; Coagulopathy
Icahn School of Medicine at Mount Sinai
 2003-10
NCT00592566 TERMINATED
Leptospirosis
Mahidol University
 2003-07 PHASE2; PHASE3
NCT00230594 COMPLETED
Primary Nocturnal Enuresis
Ferring Pharmaceuticals
 2004-07 PHASE3
NCT00902655 COMPLETED
Nocturia
Samsung Medical Center
 2004-04 PHASE4
NCT00245479 COMPLETED
Nocturnal Enuresis
Ferring Pharmaceuticals
 2002-04 PHASE4
NCT00835211 COMPLETED
Healthy
Teva Pharmaceuticals USA
 2003-07 PHASE1
NCT00111215 COMPLETED
Menorrhagia; Blood Coagulation Disorders; Blood Platelet Disorders; Von Willebrand Disease; Hematologic Disease
Centers for Disease Control and Prevention
 2001-01

(data from https://clinicaltrials.gov, updated on 2026-08-31)

Check the Desmopressin Acetate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Desmopressin selectively binds to and activates the vasopressin V2 receptor on renal collecting duct cells, stimulating intracellular cyclic AMP signaling and driving the translocation of aquaporin-2 water channels to the apical membrane. This cellular response increases renal water reabsorption and promotes endothelial hemostatic factor release, thereby suppressing excessive urine output in nocturnal enuresis and controlling surgical bleeding in clinical settings.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.